8-K: INmune Bio CEO to Speak at Maxim Growth Summit

INmune Bio's CEO, David Moss, will participate in a Dermatologic Rare Disease Panel at the Maxim Growth Summit on October 22, 2025, discussing the company's CORDStrom platform.

Summary

• INmune Bio Inc. announced that its Chief Executive Officer, David Moss, will participate in a Dermatologic Rare Disease Panel at the Maxim Growth Summit.
• The Summit, presented by Maxim Group LLC, is scheduled for October 22-23, 2025, at the Hard Rock Hotel in New York City.
• Mr. Moss will discuss INmune Bio's CORDStrom, an advanced cell platform designed for the systematic treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB), an ultra-rare pediatric disease.
• The panel is set to take place on October 22, 2025, at 8:30 AM ET.
• Mr. Moss will also be available for one-on-one meetings with attendees throughout the conference.

Sentiment

Score: 7

Explanation: The announcement of CEO participation in an investor summit is a standard corporate communication event. It provides positive visibility and an opportunity to discuss a key pipeline asset (CORDStrom) for a rare disease, which is generally viewed favorably. However, it does not contain any new financial results or significant operational updates, hence not strongly positive.

Positives

• Participation in a prominent industry summit provides increased visibility and networking opportunities for INmune Bio.
• CEO David Moss will present on CORDStrom, highlighting the company's advanced cell platform for a rare pediatric disease, potentially attracting investor interest.
• The event offers an opportunity for one-on-one meetings with investors and industry professionals, fostering direct engagement.

Risks

• Clinical trials are in early stages, and there is no assurance that any specific outcome will be achieved.
• Actual results and the timing of certain events and circumstances may differ materially from forward-looking statements due to various risks and uncertainties.
• Product candidates CORDstrom, XPro1595 (XPro, pegipanermin), and INKmune have not been approved by the US Food and Drug Administration (FDA) or any regulatory body, and there is no assurance of future approval or specific results.
• Risks and uncertainties relate to the company's ability to produce more drug for clinical trials.
• The availability of substantial additional funding is crucial for the company to continue its operations, research and development, clinical studies, and future product commercialization.
• Risks are associated with the company's business, research, product development, regulatory approval, marketing, and distribution plans and strategies.
• Other factors identified and described in more detail in the company's filings with the Securities and Exchange Commission (including Form 10-K, 10-Q, and 8-K) could cause actual future results to differ materially from current expectations.

Future Outlook

Forward-looking statements indicate that clinical trials are in early stages with no assurance of specific outcomes. The company's product candidates (CORDstrom, XPro1595, INKmune) have not yet received FDA or any regulatory body approval, and there is no guarantee of future approval or specific results. Future success is dependent on factors including the ability to produce more drug for clinical trials, the availability of substantial additional funding, and effective business, research, product development, regulatory approval, marketing, and distribution plans and strategies.

Management Comments

• David Moss, Chief Executive Officer, will participate in a Dermatologic Rare Disease Panel at the Maxim Growth Summit presented by Maxim Group LLC.
• Mr. Moss will discuss INmune Bio's CORDStrom, the company's advanced cell platform for the systematic treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB), an ultra-rare pediatric disease affecting nearly every organ in the body except the brain.

Industry Context

The biotechnology and rare disease sectors are highly dynamic, with significant investor interest in companies developing treatments for unmet medical needs. Participation in investor summits like the Maxim Growth Summit is a common strategy for clinical-stage companies to raise their profile, attract investment, and communicate progress on their pipeline, especially for rare diseases like RDEB where patient populations are small but the need is critical.

Stakeholder Impact

• Shareholders/Investors: Increased visibility for the company and its CORDStrom program, potentially leading to greater investor interest. Opportunity to hear directly from the CEO.
• Patients/Medical Community: Highlights the company's focus on developing treatments for ultra-rare diseases like RDEB.

Next Steps

• CEO David Moss to participate in the Dermatologic Rare Disease Panel on October 22, 2025.
• CEO David Moss to be available for one-on-one meetings throughout the Maxim Growth Summit (October 22-23, 2025).

Key Dates

Recommendation

This filing is a routine announcement of management participation in an industry conference. While it offers positive visibility for the company and its pipeline, it does not contain new material financial or operational information that would warrant a change in investment thesis. Investors should hold and await more substantive updates on clinical trial progress or financial performance.

Keywords

INmune Bio, INMB, Maxim Growth Summit, Dermatologic Rare Disease, CORDStrom, Recessive Dystrophic Epidermolysis Bullosa, RDEB, biotechnology, clinical-stage, inflammation, immunology, innate immune system, investor conference